US FDA News

top of page

iPharmaCenter

News | Blogs | Healthcare | Consulting

Contact: info@ipharmacenter.com

Home
Pharma
Healthcare News
Healthcare Policies
Disease News
Conferences
Others
- COVID-19
- Contact

Search

ipharmaservices

Mar 5

Tevimbra Receives U.S. Approval for First-Line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy | iPharmaCenter

0

ipharmaservices

Feb 3

AstraZeneca's ADC Enhertu is now approved in US for HR-positive, HER2-low or ultra low breast cancer | iPharmaCenter

0

ipharmaservices

Jan 29

FDA Grants Approval for Enhertu in HER2-Positive Breast Cancer Following Endocrine Therapy | iPharmaCenter

0

ipharmaservices

Jan 3

BeiGene's PD-L1 inhibitor Tevimbra approved in the US for advanced gastric or gastroesophageal junction (G/GEJ) cancers | iPharmaCenter

0

ipharmaservices

Dec 23, 2024

Lilly Secures FDA Approval for Zepbound in Obstructive Sleep Apnea, Outpacing Novo Nordisk | Pharma Breaking News | iPharmaCenter

0

ipharmaservices

Oct 13, 2024

US FDA Approved Pfizer's Hympavzi for hemophilia A or B, who do not have inhibitors | FDA Approved | iPharmaCenter

0

Roche aims to strengthen its breast cancer portfolio with the approval of Itovebi | FDA Approval | iPharmaCenter

ipharmaservices

Oct 13, 2024

Roche aims to strengthen its breast cancer portfolio with the approval of Itovebi | FDA Approval | iPharmaCenter

0

ipharmaservices

Oct 9, 2024

US FDA Approved Opdivo as perioperative treatment in patients with resectable non-small cell lung cancer | iPharmaCenter

0

ipharmaservices

Aug 24, 2024

FDA Grants Accelerated Approval to Gilead’s Livdelzi for PBC, Marking Breakthrough in Liver Disease Treatment | iPharmaCenter

0

Novartis Gains FDA Accelerated Approval for Fabhalta (iptacopan), a Complement Inhibitor for Reducing Proteinuria in Primary IgA Nephropathy (IgAN)

ipharmaservices

Aug 8, 2024

Novartis Gains FDA Accelerated Approval for Fabhalta (iptacopan), a Complement Inhibitor for Reducing Proteinuria in Primary IgA Nephropathy (IgAN)

0

ipharmaservices

Aug 8, 2024

FDA Approved Sun Pharma's Leqselvi (deuruxolitinib) for Severe Alopecia Areata

0

US FDA Approves Expanded Use of Jemperli Plus Chemotherapy for Endometrial Cancer

ipharmaservices

Aug 5, 2024

US FDA Approves Expanded Use of Jemperli Plus Chemotherapy for Endometrial Cancer

0

FDA Approves Lilly's Kisunla for Early Symptomatic Alzheimer's Disease

ipharmaservices

Jul 4, 2024

FDA Approves Lilly's Kisunla for Early Symptomatic Alzheimer's Disease

0

ipharmaservices

Jun 20, 2024

Imfinzi approved for mismatch repair deficient endometrial cancer, fifth indication for AZ's blockbuster | iPharmaCenter

0

FDA Approved Skyrizi for Ulcerative Colitis, Enhancing AbbVie's Inflammatory Bowel Disease Portfolio

ipharmaservices

Jun 19, 2024

FDA Approved Skyrizi for Ulcerative Colitis, Enhancing AbbVie's Inflammatory Bowel Disease Portfolio

0

ipharmaservices

Jun 18, 2024

FDA Approved Merck’s Keytruda Plus Chemotherapy for Advanced or Recurrent Endometrial Carcinoma

0

FDA Approved Bristol Myers Squibb’s Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma

ipharmaservices

May 31, 2024

FDA Approved Bristol Myers Squibb’s Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma

0

FDA approved BMS' Breyanzi for relapsed or refractory follicular lymphoma | iPharmaCenter

ipharmaservices

May 16, 2024

FDA approved BMS' Breyanzi for relapsed or refractory follicular lymphoma | iPharmaCenter

0

FDA Grants Complete Approval for Tivdak in Treating Recurrent or Metastatic Cervical Cancer

ipharmaservices

Apr 30, 2024

FDA Grants Complete Approval for Tivdak in Treating Recurrent or Metastatic Cervical Cancer

0

FDA Drug Approvals | 2024 | iPharmaCenter

ipharmaservices

Apr 20, 2024

FDA Drug Approvals | 2024 | iPharmaCenter

0

For sponsored articles, link insertions, and advertisements, please write to info@ipharmacenter.com

Find the latest pharma and healthcare news on Telegram now. Simply scan the QR code.

Rephrase with Ginger (Cmd+⌥+E)

iPharmaCenter Telegran_edited.jpg

bottom of page